BG62638B1 - Self-adhesive fibrine glue - Google Patents
Self-adhesive fibrine glue Download PDFInfo
- Publication number
- BG62638B1 BG62638B1 BG101279A BG10127997A BG62638B1 BG 62638 B1 BG62638 B1 BG 62638B1 BG 101279 A BG101279 A BG 101279A BG 10127997 A BG10127997 A BG 10127997A BG 62638 B1 BG62638 B1 BG 62638B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- component
- glue
- adhesive
- fibrinogen
- self
- Prior art date
Links
- 239000000853 adhesive Substances 0.000 title abstract description 3
- 239000003292 glue Substances 0.000 title abstract description 3
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 7
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 7
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 7
- 108010071289 Factor XIII Proteins 0.000 claims abstract description 6
- 102000013566 Plasminogen Human genes 0.000 claims abstract description 6
- 108010051456 Plasminogen Proteins 0.000 claims abstract description 6
- 229940012444 factor xiii Drugs 0.000 claims abstract description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 3
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 5
- 102000016359 Fibronectins Human genes 0.000 claims description 5
- 108010067306 Fibronectins Proteins 0.000 claims description 5
- 108090000190 Thrombin Proteins 0.000 abstract description 4
- 229960004072 thrombin Drugs 0.000 abstract description 4
- 230000001070 adhesive effect Effects 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 238000001356 surgical procedure Methods 0.000 abstract description 2
- 101000940468 Drosophila melanogaster COP9 signalosome complex subunit 2 Proteins 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000535 fibrinogen concentrate Substances 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940027992 calcium chloride 100 mg/ml Drugs 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940049370 fibrinolysis inhibitor Drugs 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Област на техникатаTechnical field
Изобретението се отнася до автоложно 5 фибриново лепило, което намира приложение в хирургията.The invention relates to an autologous 5 fibrin adhesive which is used in surgery.
Предшестващо състояние на техникатаBACKGROUND OF THE INVENTION
Известни са фибринови лепила с автоложен или хетероложен характер, съставени от фибриноген, тромбинкалциев двухлорид и инхибитор на фибриолизата.Autologous or heterologous fibrin adhesives known to be composed of fibrinogen, thrombin calcium dichloride and an inhibitor of fibriolysis are known.
Известен е състав на фибриново лепило, 15 който се получава от автоложна плазма /1/. Във фибриновия компонент се съдържат следните съставки: фибриноген - средно 78,4 mg/ml, фактор XIII - средно 15,8 U/ml, плазминоген - средно 113,7 pg/ml, фибронектин - средно 9624 pg/ml и 20 албумин - средно 2,7 g/gdl. Като втори компонент се използват говежди тромбин 500 U/ml и калциев двухлорид в обем, равен на първата съставка. Към втората съставка се добавя инхибитор на фибринолизата. Двете съставки се смесват в 25 момента на употреба.A composition of fibrin glue, which is obtained from autologous plasma (1) is known. The fibrin component contains the following ingredients: fibrinogen - average 78.4 mg / ml, factor XIII - average 15.8 U / ml, plasminogen - average 113.7 pg / ml, fibronectin - average 9624 pg / ml and 20 albumin - average 2.7 g / gdl. The second component is bovine thrombin 500 U / ml and calcium dichloride in a volume equal to the first ingredient. A fibrinolysis inhibitor is added to the second ingredient. The two ingredients are mixed at 25 times of use.
Първата съставка на лепилото се получава по следния начин. С апарат за плазмофереза се получава автоложна плазма в количество 8 ml/ kg тегло. Продуктът се замразява на -80°С за 12 30 h с последващо размразяване на 4°С за 16 h. Следва центрофугиране на 1000 х g за 15 min при 4°С. Продуктът се замразява отново на 80°С за 8 h и отново след това се разтопява при 4°С за 16 h. Следва центрофугиране на 1000 х g 35 за 15 min на 4°С.The first glue component is prepared as follows. Plasmapheresis apparatus produces an autologous plasma of 8 ml / kg by weight. The product was frozen at -80 ° C for 12 30 h followed by thawing at 4 ° C for 16 h. This was followed by centrifugation at 1000 x g for 15 min at 4 ° C. The product was again frozen at 80 ° C for 8 h and then melted again at 4 ° C for 16 h. This was followed by centrifugation at 1000 x g 35 for 15 min at 4 ° C.
Техническа същностTechnical nature
Съставът на автоложното фибриново ле- 40 пило съдържа като първи компонент фибриноген от 20 до 80 mg/ml, фактор XIII от 10 до 17 U/ml, плазминоген от 60 до 160 mg/ml и фибронектин от 500 до 1600 pg/ml, и като втори компонент калциеви йони от 5 до 200 mg/ml. Съотношението на компонентите е 1:1.The composition of the autologous fibrin lobe 40 contains, as a first component, fibrinogen from 20 to 80 mg / ml, factor XIII from 10 to 17 U / ml, plasminogen from 60 to 160 mg / ml and fibronectin from 500 to 1600 pg / ml, and as a second component, calcium ions from 5 to 200 mg / ml. The ratio of the components is 1: 1.
Предимствата на изобретението се състоят в това, че не се използва тромбин като втори ком-понент и по този начин се избягва възможността за реакция към чужди белтъци. Премахва се и опасността от трансмисивни инфекции /например хепатит/.The advantages of the invention are that thrombin is not used as a second component and thus the ability to react to foreign proteins is avoided. The risk of transmissible infections (such as hepatitis) is also eliminated.
При експериментални изследвания върху опитни животни фибриновото лепило показва по-добри резултати по отношение на адхезивния ефект, силата на опън и хемо- и лимфостатичните свойства.In experimental studies in experimental animals, fibrin glue showed better results in terms of adhesive effect, tensile strength, and haemostomy and lymphostatic properties.
Примерни изпълненияExemplary embodiments
ПриложениеApplication
Автоложното фибриново лепило се прилага интраоперативно след извършване на лимфна дисекция при болни от рак на млечната жлеза, като се изтеглят по стерилен начин от 5 до 15 ml от фибриногеновия концентрат. В отделна спринцовка се изтеглят от 5 до 10 ml калциев глюконат и 10 000 единици фибринолитик - апротинин. Върху оперативното поле последователно се нанасят първоначално калциевият препарат и фибринолитикът, а веднага след тях - фибриногеновият концентрат. Следва послойно зашиване на оперативната рана.Autologous fibrin glue is administered intraoperatively after lymphoid dissection in breast cancer patients, by sterile withdrawal of 5 to 15 ml of fibrinogen concentrate. 5 to 10 ml of calcium gluconate and 10,000 units of fibrinolytic - aprotinin are withdrawn in a separate syringe. Initially, the calcium preparation and the fibrinolytic were applied sequentially to the operative field, followed immediately by the fibrinogen concentrate. Following is a layer-by-layer suturing of the operative wound.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG101279A BG62638B1 (en) | 1997-03-04 | 1997-03-04 | Self-adhesive fibrine glue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG101279A BG62638B1 (en) | 1997-03-04 | 1997-03-04 | Self-adhesive fibrine glue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG101279A BG101279A (en) | 1998-10-30 |
| BG62638B1 true BG62638B1 (en) | 2000-04-28 |
Family
ID=3926900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG101279A BG62638B1 (en) | 1997-03-04 | 1997-03-04 | Self-adhesive fibrine glue |
Country Status (1)
| Country | Link |
|---|---|
| BG (1) | BG62638B1 (en) |
-
1997
- 1997-03-04 BG BG101279A patent/BG62638B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BG101279A (en) | 1998-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6168788B1 (en) | Fibrin glue without fibrinogen and biosealant compositions and methods | |
| US5605887A (en) | Therapeutic fibrinogen compositions | |
| Martinowitz et al. | Fibrin sealant in surgery of patients with a hemorrhagic diathesis | |
| Brennan | Fibrin glue | |
| US5702715A (en) | Reinforced biological sealants | |
| US5290552A (en) | Surgical adhesive material | |
| AU724715B2 (en) | A stabilized mixture comprising fibrinogen | |
| US5510102A (en) | Plasma and polymer containing surgical hemostatic adhesives | |
| EP0968008B1 (en) | A stabilized mixture comprising fibrinogen | |
| JPH0271747A (en) | Surgical adhesive material | |
| EP2130549B1 (en) | Solid fibrinogen preparation | |
| JPH0696039B2 (en) | Tissue adhesive and method for producing the same | |
| WO1996040033A1 (en) | Non-biological patch for hemostasis | |
| EP3370785B1 (en) | Hemostatic composition | |
| JPS6139824B2 (en) | ||
| AU2004206150A1 (en) | Hemostatic materials | |
| US20090123453A1 (en) | Pharmaceutical Preparations And Medicines Capable Of Generating, And/Or Containing, Thrombin | |
| EP0466383A1 (en) | A collagen medical adhesive and its uses | |
| Ünlü et al. | Comparison of the topical haemostatic agents for the prevention of suture hole bleeding. An experimental study | |
| US8124075B2 (en) | Enhanced biological autologous tissue adhesive composition and methods of preparation and use | |
| JPH0199565A (en) | Fibrin glue preparation kit | |
| US7494971B2 (en) | Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin | |
| BG62638B1 (en) | Self-adhesive fibrine glue | |
| Burnouf | Blood-derived, tissue engineering biomaterials | |
| Padovan et al. | Fibrin adhesive implant in wound healing repair of dental sockets with topical application of epsilon aminocaproic acid: histological analysis |